Dupilumab Step-down Strategy to Maintain Remission in Adult and Adolescents Patients With Atopic Dermatitis

Inclusion Criteria:

• Age ≥ 12 years

• Moderate to severe AD treated with dupilumab every 2 weeks

• Written informed consent (patient and/or person who has parental authority)

• Dupilumab treatment for at least one year

• Controlled AD (ADCT<7 and IGA ≤ 2) and assessed as controlled by the investigatorsince at least 6 months without tapering dosage of dupilumab

• Amount of topical treatment (TCS or calcineurin inhibitor) stable for 6 months andless than 60 g/month

Exclusion Criteria:

• Patients with Side effects of dupilumab

• Non controlled AD: ADCT ≥ 7 or IGA ≥ 3

• Female patient must not be pregnant*, breastfeeding or considering becoming pregnant

• Patient under judicial protection

• Adults under guardianship or trusteeship